NRx Pharmaceuticals (NASDAQ:NRXP) Updates FY 2023 Earnings Guidance

NRx Pharmaceuticals (NASDAQ:NRXP) updated its FY 2023 earnings guidance on Thursday. The company provided earnings per share guidance of -0.400–0.400 for the period, compared to the consensus earnings per share estimate of -0.370. The company issued revenue guidance of -.

NRx Pharmaceuticals Trading Down 2.9 %

NASDAQ:NRXP opened at $0.51 on Thursday. The company’s fifty day moving average price is $0.46 and its 200-day moving average price is $0.38. NRx Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $1.20.

Institutional Trading of NRx Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new position in NRx Pharmaceuticals during the first quarter valued at $25,000. HRT Financial LP purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $29,000. Citigroup Inc. lifted its stake in shares of NRx Pharmaceuticals by 355.1% in the first quarter. Citigroup Inc. now owns 15,208 shares of the company’s stock worth $37,000 after buying an additional 11,866 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of NRx Pharmaceuticals by 10,884.4% in the fourth quarter. Bank of America Corp DE now owns 35,809 shares of the company’s stock worth $40,000 after buying an additional 35,483 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $49,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression.